Navigation Links
Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Date:3/11/2008

LEXINGTON, Mass., March 11 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced the Company will be presenting at the Cowen and Company 28th Annual Health Care Conference, on Tuesday, March 18, 2008 at 1:40 pm ET. The conference is being held in Boston, Massachusetts. The presentation will be web cast live and may be accessed by visiting the Investors section of the Indevus website at http://www.indevus.com.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA XR(TM) and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
2. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Announces Allergan as New Partner for SANCTURA Brand
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
8. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)... EDMONTON, Sept. 4 / BioMS ...e treatment of multiple sclerosis (MS), today,anno...of the United States,has granted fast track design...8298), for the treatment of secondary progressive ... evaluated in a U.S. pivotal phase III trial,name...
(Date:9/4/2008)...-FirstCall/ -- Repligen Corporation,(Nasdaq: RGEN...1.125 million,in research grants to support the de...a. The grants are comprised of $1 million from the... from the Friedreich,s,Ataxia Research Foundation ...he grants will further the development, characteri...
(Date:9/4/2008)...RNewswire/ -- Thomson Reuters, the,world,s leading...and,professionals, announced today that the Nation... of scientists worldwide using BIOMARKERcenter, th...ligence to provide,pharmaceutical, biotechnology, ...ework for assessing and tracking a potential bioma...
(Date:9/3/2008)...Full Year Guidance, SHENZHEN, China, Sept. 3 /Xin...national Limited (NYSE: MR ), a leading developer...ldwide today announced its selected,unaudited fina..., 2008.,During the quarter, Mindray successfully c...ent monitoring business. The financial results,rep...
Breaking Biology Technology:BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 2Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 3Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 4Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program 5The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters 2The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters 3Mindray Medical International Announces Second Quarter 2008 Results 2Mindray Medical International Announces Second Quarter 2008 Results 3Mindray Medical International Announces Second Quarter 2008 Results 4Mindray Medical International Announces Second Quarter 2008 Results 5Mindray Medical International Announces Second Quarter 2008 Results 6Mindray Medical International Announces Second Quarter 2008 Results 7Mindray Medical International Announces Second Quarter 2008 Results 8Mindray Medical International Announces Second Quarter 2008 Results 9Mindray Medical International Announces Second Quarter 2008 Results 10Mindray Medical International Announces Second Quarter 2008 Results 11Mindray Medical International Announces Second Quarter 2008 Results 12Mindray Medical International Announces Second Quarter 2008 Results 13Mindray Medical International Announces Second Quarter 2008 Results 14Mindray Medical International Announces Second Quarter 2008 Results 15Mindray Medical International Announces Second Quarter 2008 Results 16Mindray Medical International Announces Second Quarter 2008 Results 17
...ittee of the Wisconsin Legislature held a hearin...ent programs, Florida Gov. Jeb Bush announced hi...or biomedical institute to open a center in Orland...differing philosophies about state business growth...mittee met to hear an audit report that concluded...
...ed annual and quarterly earnings reports, Merge H...on The N asdaq Stock Market . , ,The company rec...Friday, stating that the stock market,s Listing Qu...listing of the stock. , ,Merge, a medical imaging ...been working to catch up with missed filing deadli...
...ss community fear that changing the legal framewor...ould stifle research. , ,The U.S. House Small Bus...t would give small companies majority-owned by ven...Innovation Research grants. , ,The SBIR program di...s with less than 500 employees, regularly developi...
...udents are again among the nation,s elite when it ...e preparedness test. With an average score of 22.2...onally among states that depend on the ACT, fallin...rst-place Minnesota. , ,While high average scores ...ols, all states, from Minnesota and Wisconsin on d...
Other Biology Technology:Going for the "Big Score" or hedging your bets: Two economic development strategies 2Going for the "Big Score" or hedging your bets: Two economic development strategies 3Going for the "Big Score" or hedging your bets: Two economic development strategies 4Venture-backed firms could become eligible for federal SBIR grants 2Venture-backed firms could become eligible for federal SBIR grants 3Venture-backed firms could become eligible for federal SBIR grants 4Wisconsin students test well on ACT, but relatively few are ready for college rigors 2Wisconsin students test well on ACT, but relatively few are ready for college rigors 3
(Date:9/4/2008)... , What: , The CTRC-AACR San Antonio Breast Can...dings in laboratory, translational and clinical br...on new and promising therapeutic approaches, as we...ing breast cancer. , To help you take the best a...nd related activities, we encourage you to visit ...
(Date:9/4/2008)... ,, Why is it that the origins of many serio... question, a scientist at the University of Califo...h a unified molecular view of the indivisible unit..., Reviewing findings from multiple disciplines, ...ular and Molecular Medicine and Investigator with ...
(Date:9/3/2008)... , , President George W. Bush has named the r...he nation,s highest honor for science and engineer...ouse ceremony on Sept. 29, 2008. , "The 2007 Nat...to American science with their superb research," s... Science Foundation (NSF). "Their legacies have im...
(Date:9/3/2008)... , , Mexico City once topped lists of places with...forts to curb emissions have improved the situatio...ir. Now, atmospheric scientists from UC San Diego ... pall that hangs over the city to precisely identi...patterns of changes to the mix. , This forensic ...
Breaking Biology News(10 mins):Do 68 molecules hold the key to understanding disease? 2White House announces 2007 National Medal of Science laureates 2Smoke smudges Mexico City's air, chemists identify sources 2Smoke smudges Mexico City's air, chemists identify sources 31976 Italian Dioxin Release Damaged Babies Thyroids 24902 1Tysabri Lawyers Pulaski 26amp 3B Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects 24899 1Tysabri Lawyers Pulaski 26amp 3B Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects 24899 2Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008 2009 Season in the US 2766 1Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008 2009 Season in the US 2766 2Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008 2009 Season in the US 2766 3Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008 2009 Season in the US 2766 4Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008 2009 Season in the US 2766 5Estimate of Annual HIV Incidence Increases Significantly 3B New Estimate Will Show Need For a National AIDS Strategy 24894 1Estimate of Annual HIV Incidence Increases Significantly 3B New Estimate Will Show Need For a National AIDS Strategy 24894 2Estimate of Annual HIV Incidence Increases Significantly 3B New Estimate Will Show Need For a National AIDS Strategy 24894 3
...ty College London) scientists has designed a new d...e protein (CRP), a protein that contributes to tis...ings, published in the journal Nature, suggest tha...g-term clinical benefits following a heart attack....blood but its concentration increases sharply in a...
...lights strong results from a single study at the c... low-cost drug Bactrim to help HIV-infected childr...ical literature on the preventive use of Bactrim -...ine cotrimoxazole -- for children to ward off comm... immune system is weakened by HIV. , Dr. Kate Gr...
...rally agree that many types of protected areas wil...little is known about the comparative performance ...he most extreme form of forest disturbance: conver...hed in Conservation Biology (2006, Vol 20, pages 6... Daniel Nepstad of the Woods Hole Research Center ...
...f Medicine have found evidence that a hormone prod... brain functions of spatial learning and memory de...best on an empty stomach. , Published in the Febru...stigators at Yale and other institutes, the study ...tomach and previously associated with growth hormo...
Other Biology News:New drug could reduce tissue damage after heart attack 2Low-cost drug gaining favor for use in HIV-infected children in poor countries 2Satellites show Amazon parks, indigenous reserves stop forest clearing 2Satellites show Amazon parks, indigenous reserves stop forest clearing 3Learning and memory stimulated by gut hormone 2
...rators set the standard for centrifugal concentrat...ac uses a combination of centrifugal force, heat a..., SC110A comes equipped with:, , TEFLON-coated R...ity , Three Selectable Heating Levels optim...
Digital display of time, vacuum and temperature , Dual vacuum control of ramping rate and ultimate level , Comes complete with RH40-12 (40 x 1.5 ml) Rotor and (2) Glass Condensation Flasks.
Explorer Software Suite. Complete software and PC for datalogging, programming, control and monitoring for Explorer SpeedVac System [please inquire for latest PC configuration] from Thermo Scientific
...m concentrators/centrifugal evaporators offers a w... rapid and safe concentration of heat-labile sampl... or high vacuum pumps, a choice of cold traps and ...s by transfer), ensuring solvent recovery and samp...
Biology Products: